Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 84 companies set new 52-week lows.
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial
Atai Update: Ketamine Trials Are Ongoing, Company Cuts 30% Workforce
The clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) founded in 2018 shared updates on the two clinical trials as well as its plan to streamline its workforce with significant layoffs.
Here Are The Year’s Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
GAINERS: LOSERS: Intelgenx Technologies (OTC:IGXT) shares closed down 7.06% at $0.23 Cybin (AMEX:CYBN) shares closed down 4.73% at…
Top 3 Psychedelic Storylines To Watch In 2023
This article by James Hallifax was originally published on Microdose and appears here with permission.
EXCLUSIVE: Defining ‘Natural’ Psychedelics, State Regulations & Ayahuasca’s Benefits
(Part three of a three-part series)
See previous stories:
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
This Analyst Still Has Confidence In Atai Life Sciences’ Pipeline Despite Recent Setbacks
HC Wainwright lowered the price target for Atai Life Sciences N.V. (NASDAQ:ATAI) from $50 to $20 to reflect recent adverse outcomes in programs…